News Related to OX40L

Related coverage linked through entity extraction aliases.

AAD 2026 and pipeline updates highlight new atopic dermatitis treatment data

Apr 21, 2026

Atopic dermatitis updates in 2026 included long-term upadacitinib safety, phase 3 amlitelimab and rademikibart data, and 5-year interim dupilumab results in children. A market report also listed multiple emerging therapies in late-stage development.

Alopecia Areata Market Expected to Expand by 2036 with Novel Therapies in Development

Mar 04, 2026

The alopecia areata treatment market is projected to grow significantly through 2036, driven by rising prevalence and the anticipated launch of emerging therapies including JAK inhibitors and novel drug classes targeting immune pathways.